After a few weeks of treatment he felt better but a few months later he fell ill again, this time with potentially life-threatening TB symptoms.
Watch Evans share his story in the video below.
Tuberculosis claimed the lives of an estimated 1.5 million people in 2020. It is the second leading cause of death from an infectious disease after COVID-19, and before AIDS-related illness. Millions more people suffer life-changing effects as severe damage to their lungs leaves them unable to lead an active, healthy life.
An estimated 1.7 billion people worldwide live with latent TB, usually without symptoms. However, approximately 5-10% of people will go on to develop active TB, which requires urgent medical attention. Increasing access to treatment for latent TB can avert the development of active TB.
Historically, treatment for active TB has often involved taking hundreds of pills over up to three years. The pills often have unpleasant side-effects, contributing to relatively low treatment completion rates for TB. These low rates leave people at risk of reinfection and have also led to a worrying rise in multidrug-resistant and extensively-drug resistant TB. This is why treating latent TB before it becomes active is so important.
HIV viral load testing is the best way for doctors to know if the treatment they prescribe is effective. But access to viral load testing technology is far from equal.
On November 15, the Clinton Health Access Initiative (CHAI), MedAccess, and SD Biosensor announced a partnership to increase access to rapid diagnostic tests for syphilis and HIV.
The longer a mosquito population is exposed to a single class of insecticides, the longer it has had to build resistance. Dr. Tom McLean from IVCC explores three insecticide tools at market and in development to battle resistance.